Table 4.
Regimens used for salvage therapy, per country
| Regimen | Number of respondents, na,b | |||||
|---|---|---|---|---|---|---|
| France | Germany | Italy | Spain | UK | Total, n (%) | |
| N = 15 | N = 15 | N = 15 | N = 15 | N = 15 | N = 75 | |
| Published regimens | ||||||
| Augmented hyper-CVAD | 3 | 1 | 2 | 5 | 11 (15) | |
| CALGB 8811/Larson | 1 | 1 | 1 | 3 (4) | ||
| EORTC ALL-3 (induction phase) | 1 | 2 | 3 (4) | |||
| FLAG-AMSA | 1 | 1 | 2 (3) | |||
| FLAG-IDA | 1 | 2 | 6 | 9 (12) | ||
| GMALL 07/03 | 6 | 1 | 7 (9) | |||
| GRAALL 02/2005 (salvage phase) | 2 | 1 | 3 (4) | |||
| GRAALL 2003 (salvage phase) | 1 | 2 | 3 (4) | |||
| Hyper-CVAD | 1 | 1 | 1 | 1 | 4 (5) | |
| MRC UK ALL XII/ECOG 2993 | 1 | 3 | 4 (5) | |||
| PETHEMA ALL-96 | 2 | 2 (3) | ||||
| Modified published regimens | ||||||
| FLAG-IDA | 1 | 2 | 3 (4) | |||
aRespondents could select multiple guidelines regimens
bPublished regimens reported by one respondent were: EORTC ALL3 (salvage); GIMEMA 0288 (induction phase); GIMEMA 0288 (salvage); GIMEMA-LAL0904 (induction phase); GIMEMA-LAL0904 (salvage); GRAALL 02/2005 (induction phase); LALA-94; nelarabine/cyclophosphamide; PALG 5–2007 (Induction II); VANDEVOL; modified published regimens reported by one respondent were: aBFM; augmented hyper-CVAD; CALGB 8811/Larson; GRAALL 02/2005 (induction phase); LALA-94; MRC UK ALL XII/ECOG 2993; PETHEMA ALL-96; RWGALS – NP1 (Induction I); VANDEVOL; ongoing clinical trials reported by one respondent were: NCT01564784 and UKALL 2011 trial
aBFM, augmented Berlin-Frankfurt-Muenster; ALL, acute lymphoblastic leukaemia; CALGB, Cancer and Leukemia Group B; CVAD, cyclophosphamide, vincristine, doxorubicin (Adriamycin), dexamethasone; ECOG, Eastern Cooperative Oncology Group; EORTC, European Organization for Research and Treatment of Cancer; FLAG-AMSA, fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor-amsacrine; FLAG-IDA, fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor-idarubicin; GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adulto (Italian Group for Haematological Diseases in Adults); GMALL, German Multicenter Study Group for Adult ALL; GRAALL, Group for Research in Adult Acute Lymphoblastic Leukemia; LALA, Leucémie Aiguës Lymphoblastique de l’Adulte (Acute Lymphoblastic Leukemia in Adults); MRC UKALL XII, Medical Research Council Acute Lymphoblastic Leukemia Trial XII; PALG, Polish Adult Leukemia Group; PETHEMA, Programa para el Estudio de la Terapéutica en Hemopatía Maligna (Program for Study and Treatment of Malignant Hemopathies); RWGALS-NP1, Romanian Working Group for Acute Leukemia Study National Protocol 1; VANDEVOL, etoposide, clofarabine, asparaginase, mitoxantrone, and dexamethasone